Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data

被引：0
|
作者：
De Seze, J. [1 ,2 ]
Edan, G. [3 ]
Moreau, T. [4 ]
Brochet, B. [5 ]
Sedel, F. [6 ]
Tourbah, A. [7 ]
机构：
[1] CHU Strasbourg, Dept Neurol, INSERM 1434, Strasbourg, France
[2] CHU Strasbourg, Clin Invest Ctr, Strasbourg, France
[3] CHU Rennes, Serv Neurol, Rennes, France
[4] Dijon Univ Hosp, Dept Neurol, Dijon, France
[5] CHU Pellegrin, Dept Neurol, Bordeaux, France
[6] MedDay Pharmaceut, Paris, France
[7] CHU Reims, Dept Neurol, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P592
引用
收藏
页码：287 / 288
页数：2
相关论文
共 50 条
  • [1] Effect of MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive MS: 36-Month Follow-up Data
    Vukusic, Sandra
    de Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Simon, Olivier
    Lasser, Robert
    Tourbah, Ayman
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 32 - 33
  • [2] Effect of MD1003 (high dose pharmaceutical grade Biotin) for the treatment of progressive MS: long-term safety data at 48 months of follow-up
    De Seze, J.
    Edan, G.
    Moreau, T.
    Sedel, F.
    Tourbah, A.
    Krijnen, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 860 - 860
  • [3] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Long-term Safety Data at 48 Months of Follow-up
    De Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Sedel, Frederic
    Tourbah, Ayman
    [J]. NEUROLOGY, 2019, 92 (15)
  • [4] Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-up data
    Vukusic, S.
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Lasser, R.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 401 - 402
  • [5] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: long-term safety data at 60 months of follow-up
    de Seze, J.
    Edan, G.
    Moreau, T.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 773 - 774
  • [6] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months
    De Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Sedel, Frederic
    Tourbah, Ayman
    [J]. NEUROLOGY, 2019, 92 (15)
  • [7] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
    Ciron, J.
    Pignolet, B.
    Bucciarelli, F.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
  • [8] Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS
    Faure, J.
    Jauffret, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 281 - 282
  • [9] High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration
    Nessler, S.
    Winkler, A.
    van der Meer, F.
    Gargareta, S.
    Cobos, A.
    Stadelmann, C.
    Nave, K. A.
    Brueck, W.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 311 - 311
  • [10] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Sedel, Frederic
    Lublin, Fred
    [J]. NEUROLOGY, 2020, 94 (15)
12345